Inspiringly, senescent tumor cells that avoid NK cell immunity by shedding NKG2D ligands or increasing HLA‐E molecules could be targeted with developing antibodies that block NKG2A checkpoint or prevent NKG2D ligand MICA/B shedding.200, 277, 278, 279. The gene discussed is KLRK1; the disease is neoplasm.